BIOCON

Biocon : Co Completes Buyout of Biocon Biologics; Stake Rises to ~98% • 🧬 Acquisition Completed: Biocon completed acquisition of the remaining 7.18 crore equity shares of Biocon Biologics (BBL) from Mylan Inc. • 💵 Deal Value: Transaction executed for USD 200 million (cash consideration), following the earlier tranche. • 🏢 Near-Total Ownership: Post-acquisition, Biocon now holds ~98% of BBL’s fully diluted equity capital, strengthening control. • 📈 Strategic Consolidation: Full consolidation enhances strategic flexibility, capital allocation efficiency, and long-term value creation in biosimilars. • 🌍 Biosimilars Focus: Strengthens Biocon’s position in the global biologics and biosimilars market with clearer parent-subsidiary structure. 🟢 Impact: Positive Higher ownership and full control over Biocon Biologics improves strategic clarity, earnings visibility, and long-term growth potential in the biologics business.